Please login to the form below

Not currently logged in
Email:
Password:

Sarepta Therapeutics

This page shows the latest Sarepta Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Roche to collaborate with Dyno on gene therapies for CNS/liver diseases

Roche to collaborate with Dyno on gene therapies for CNS/liver diseases

The Roche deal is Dyno’s third pharma collaboration, in addition to its existing partnerships with Novartis and Sarepta Therapeutics. ... disease. The Sarepta deal is focused on the development of new AAV vectors for gene therapies aimed at targeting

Latest news

More from news
Approximately 7 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody therapeutics. ... Licence. 145. Sarepta Therapeutics/  Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Prosensa has just begun a rolling submission of the application. BioMarin clearly feels that there is still a real opportunity and is prepared to take on Sarepta and PTC Therapeutics in ... This month also saw CAR-T “wunder-kid” Juno Therapeutics

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....